Endo, Inc.

OTCPK:ENDP.Q Rapport sur les actions

Capitalisation boursière : US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Gestion

Gestion contrôle des critères 3/4

Le PDG Endo International est Blaise Coleman, nommé en Dec2016, a un mandat de 7.42 ans. La rémunération annuelle totale est $ 12.85M, composée du salaire de 7.6% et des bonus 92.4%, y compris les actions et options de la société. détient directement 0.18% des actions de la société, d'une valeur de $ 253.23. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 7 ans.

Informations clés

Blaise Coleman

Directeur général

US$12.8m

Rémunération totale

Pourcentage du salaire du PDG7.61%
Durée du mandat du directeur général7.4yrs
Propriété du PDG0.2%
Durée moyenne d'occupation des postes de direction4.8yrs
Durée moyenne du mandat des membres du conseil d'administration7yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Aug 16

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Endo International (NASDAQ:ENDP) creditors are looking at putting the pharma company up for sale through a bankruptcy, likely through a Chapter 11 filing in New York, Bloomberg reported. Endo (ENDP) has a debt load of more than $8B and is still facing many lawsuits over its alleged role in the nation's opioid epidemic. A bankruptcy filing would make it easier for Endo (ENDP) to make deals with with governments and other entities suing the company. Bloomberg said that some first-lien lenders are competing to use their debt holdings toward a bid for the company’s assets. Seeking Alpha contributor CashFlow Hunter, which has a strong sell rating on Endo (ENDP), has said a bankruptcy filing is imminent.
Seeking Alpha • Aug 03

Endo International sees 23% rise on 3x higher than normal volume

Shares of Endo International (NASDAQ:ENDP) have risen sharply and are up 23% Wednesday afternoon amid three times higher than usual daily volume. The drugmaker's average daily volume is ~46.2M shares. As of 215p ET, more than 138M shares had traded hands. Endo (ENDP) is also having unusual options trading volume that is six times the daily normal. Seeking Alpha contributor CashFlow Hunter says the company is a strong sell with a bankruptcy filing likely.
Seeking Alpha • Jul 25

Endo outperforms defying bankruptcy fears and generic entry

The shares of Endo International (NASDAQ:ENDP) rose sharply on Monday even as the company continues to grapple with concerns over the generic threat to a key drug, failure to fulfill debt commitments, and potential bankruptcy filing amid ongoing opioid litigation. Despite an ~89% YTD decline, Endo (ENDP) has added ~13% over the past 30 days outperforming the broader market, as shown in this graph. The upsurge comes despite a recent WSJ report on the company’s plan to file for Chapter 11 bankruptcy without striking a settlement on thousands of opioid claims. In June, Dublin, Ireland-based Endo (ENDP) opted to skip interest payments owed to its junior bondholders citing the ongoing talks with certain creditors regarding its decision to evaluate strategic alternatives. A decline in earnings, driven in part by the loss of exclusivity for its leading sales generator, Vasostrict, has exacerbated the operational issues. In May, Piper Sandler downgraded Endo (ENDP), noting the generic competition to the vasopressin injection, which added $155.9M to the company topline in 1Q 2022 with ~30% YoY decline.
Seeking Alpha • Jul 12

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International (NASDAQ:ENDP) shares plunged ~20% Tuesday after The Wall Street Journal reported that the generic drugmaker is advancing towards a bankruptcy filing without reaching a settlement on opioid claims against the company. According to people familiar with the matter, despite years of negotiations with opioid claimants, Endo (ENDP) is weighing chapter 11 bankruptcy to restructure its over $8B debt and thousands of ongoing litigations. Endo (ENDP) has been negotiating with a group of senior creditors after the company missed interest payments to junior bondholders last month, the people said, adding that the management expects to reach a deal with them before a near-term bankruptcy process starts. However, a bankruptcy filing is unlikely if the company inks agreements with junior bondholders and opioid plaintiffs, the people said, noting that the situation could change. Endo (ENDP) declined to comment. Read: “Bankruptcy filing should be imminent” for Endo (ENDP), Seeking Alpha contributor CashFlow Hunter predicted in May.
Seeking Alpha • Jun 29

Endo International cools off, giving back some of its 85% Tuesday gain

Shares of Endo International are down 24% in Wednesday afternoon trading, a day after the pharma closed up 85%. The reason for Tuesday's surge was a news release issued by law firm White & Case on behalf of a group of institutional investors holding unsecured notes in Endo (NASDAQ:ENDP) subsidiaries. The group has proposed that the company commence a cash tender offer or commence a debt-for-debt exchange. Also, it is against a near-term bankruptcy filing as Endo (ENDP) has strong liquidity and it "could destroy significant value for stakeholders." Endo (ENDP) has been struggling as a result of multi-million-dollar settlements in state opioid crisis cases.
Seeking Alpha • May 10

Endo: Stick A Fork In It

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should be imminent.
Seeking Alpha • Mar 07

Endo: About As Bad As It Gets

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option.
Seeking Alpha • Dec 16

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 million of high margin sales last year. Eagle expects 180-day marketing exclusivity for vasopressin. Continue to see the stock as high risk.
Seeking Alpha • Nov 02

Endo: A Win In California But Equity Value Still A Question

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. Leverage remains too high, particularly with Vasostrict EBITDA at risk. Bankruptcy is now likely off the table but struggle to see equity value.
Seeking Alpha • Aug 31

Endo International: Loses Vasostrict Trial

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Approximately 30% of Endo Pharmaceuticals' revenue and EBITDA will take a hit. The loss likely wipes out any equity value for Endo and impairs unsecured bonds.
Seeking Alpha • Aug 20

Endo International: Hires Restructuring Advisor

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing.
Seeking Alpha • Aug 07

Endo International: All About Ongoing Litigation

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. Quarter operationally solid, but questions remain on market acceptance of QWO.
Seeking Alpha • Jul 15

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likely bankruptcy filing.
Seeking Alpha • Jun 30

Endo International: Bankruptcy Seems Like The Only Practical Option

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial begins on July 26 in Tennessee. Plaintiffs are seeking $2.4 billion. A trial for a suit against the company begins in New York on June 28th and a California trial is ongoing. A bankruptcy filing is very likely the only way to settle all of these cases in a manner that preserves value.

Analyse de la rémunération des PDG

Comment la rémunération de Blaise Coleman a-t-elle évolué par rapport aux bénéfices de Endo International?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2023n/an/a

-US$2b

Sep 30 2023n/an/a

-US$252m

Jun 30 2023n/an/a

-US$942m

Mar 31 2023n/an/a

-US$3b

Dec 31 2022US$13mUS$978k

-US$3b

Sep 30 2022n/an/a

-US$3b

Jun 30 2022n/an/a

-US$3b

Mar 31 2022n/an/a

-US$681m

Dec 31 2021US$29mUS$913k

-US$569m

Sep 30 2021n/an/a

US$129m

Jun 30 2021n/an/a

US$109m

Mar 31 2021n/an/a

US$137m

Dec 31 2020US$7mUS$829k

US$247m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$75m

Mar 31 2020n/an/a

-US$190m

Dec 31 2019US$4mUS$612k

-US$361m

Sep 30 2019n/an/a

-US$418m

Jun 30 2019n/an/a

-US$522m

Mar 31 2019n/an/a

-US$477m

Dec 31 2018US$3mUS$569k

-US$962m

Sep 30 2018n/an/a

-US$968m

Jun 30 2018n/an/a

-US$921m

Mar 31 2018n/an/a

-US$2b

Dec 31 2017US$4mUS$546k

-US$1b

Rémunération vs marché: La rémunération totale de Blaise ($USD 12.85M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 649.34K ).

Rémunération et revenus: La rémunération de Blaise a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Blaise Coleman (49 yo)

7.4yrs
Titularisation
US$12,849,847
Compensation

Mr. Blaise A. Coleman serves as President, Chief Executive Officer and Director of Endo Inc. Mr. Blaise serves as President, Chief Executive Officer and Director at Endo International plc since March 06, 2...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Blaise Coleman
President7.4yrsUS$12.85m0.18%
$ 253.2
Matthew Maletta
Executive VP9yrsUS$4.25m0.15%
$ 210.7
James Tursi
Executive Vice President of Global Research & Development2.3yrsUS$6.36mpas de données
Mark Bradley
Executive VP & CFO4.2yrsUS$7.98mpas de données
Frank Raciti
VP, Controller & Chief Accounting Officerno datapas de donnéespas de données
Cheryl Stouch
Senior VP of Information Technology & Chief Information Officer1.9yrspas de donnéespas de données
Laure Park
Senior Vice President of Investor Relations & Corporate Affairs5.8yrspas de donnéespas de données
Susan Williamson
Senior VP & Chief Compliance Officer6.1yrspas de donnéespas de données
Tracy Basso
Chief Human Resources Officer4.8yrspas de donnéespas de données
Patrick Barry
Executive VP & President of Global Commercial Operations7.4yrsUS$7.78mpas de données
James Papp
Head of Endo Ventures Limited & Senior VP of Global Supply Chain3.5yrspas de donnéespas de données
Michael McGuinness
Global Head of Quality & Compliance1.9yrspas de donnéespas de données
4.8yrs
Durée moyenne de l'emploi
54yo
Âge moyen

Gestion expérimentée: L'équipe de direction de ENDP.Q est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Blaise Coleman
President4.2yrsUS$12.85m0.18%
$ 253.2
Mark Barberio
Independent Chairman4.3yrsUS$840.00k0.016%
$ 22.9
Michael Hyatt
Independent Director10.3yrsUS$625.00k0.15%
$ 213.3
William Montague
Independent Director10.3yrsUS$625.00k0.042%
$ 59.3
Shane Cooke
Independent Director9.8yrsUS$505.00k0.043%
$ 60.0
Jennifer Chao
Independent Director3.3yrsUS$480.00k0.011%
$ 14.9
Nancy Hutson
Independent Director10.3yrsUS$505.00k0.047%
$ 65.8
Mary Smith
Independent Non-Executive Director3.8yrsUS$480.00k0.014%
$ 19.7
7.0yrs
Durée moyenne de l'emploi
61yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ENDP.Q sont considérés comme expérimentés (ancienneté moyenne 7 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/05/02 09:35
Cours de l'action en fin de journée2024/05/02 00:00
Les revenus2023/12/31
Revenus annuels2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Endo, Inc. est couverte par 32 analystes. 0 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research